Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$37.06 – $48.64
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $558.00B | $611.14B | $684.40B | $726.42B | $755.41B | $827.70B | $964.99B | $1.01T |
| Cost of revenue | $447.68B | $489.35B | $549.42B | $581.31B | $603.97B | $658.98B | $776.68B | $798.11B |
| Gross profit | $110.32B | $121.78B | $134.98B | $145.11B | $151.45B | $168.72B | $188.31B | $213.28B |
| Gross margin | 19.8% | 19.9% | 19.7% | 20.0% | 20.0% | 20.4% | 19.5% | 21.1% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $22.75B | $24.77B | $29.09B | $33.15B | $29.80B | $30.13B | $31.50B | $40.40B |
| EBITDA | $34.63B | $40.17B | $44.03B | $52.44B | $48.21B | $50.19B | $53.74B | $64.86B |
| Net income | $17.63B | $19.18B | $21.43B | $27.16B | $23.16B | $23.80B | $24.45B | $30.98B |
| Net margin | 3.2% | 3.1% | 3.1% | 3.7% | 3.1% | 2.9% | 2.5% | 3.1% |
| EPS (diluted) | 445.29 | 484.48 | 541.30 | 685.77 | 584.74 | 600.95 | 308.61 | 390.86 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $1.16T | $409.81 | $392.99–$420.93 | 1 |
| 2028 | $1.24T | $431.81 | $414.08–$443.52 | 1 |
| 2029 | $1.35T | $505.49 | $484.73–$519.19 | 1 |
| 2030 | $1.45T | $536.23 | $514.21–$550.77 | 1 |
Forward consensus · source: Financial Modeling Prep
COSMOS PHARM CORP ORD
No one on the platform currently holds CSMYF.
No tracked institution reports a position in CSMYF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-29 | $37.5000 | |
| 2025-11-28 | $37.5000 | 2026-02-12 |
| 2025-05-30 | $37.5000 | 2025-08-04 |
| 2024-11-29 | $32.5000 | 2025-02-12 |
| 2024-05-31 | $60.0000 | 2024-08-01 |
| 2023-11-29 | $60.0000 | 2024-02-13 |
| Execution date | Ratio |
|---|---|
| 2024-08-29 | 2-for-1 |
| 2020-05-28 | 2-for-1 |
No one on the platform has traded CSMYF yet.
| $4.2B |
| — |
| GEDSFGedeon Richter PLC | $24.85 | +0.00% | $4.5B | — |
| GNGBFGetinge AB (publ) | $20.05 | +0.00% | $5.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$CSMYF Little bit of a bounce in intellia etc. just under $14 now $NTLA cosmo pharmaceuticals announced their quarterly results. The stock is down significantly today. I’d look to purchase shares (buy and hold) in the next month or two before spring 12 month safety data is released on what I believe will be a (mega) blockbuster topical drug for male pattern hair loss. Stock had almost doubled after phase 3 results so looks like a good time to buy. Going to see where my cash is at then *will have to enable international trading - this is easy to do on your regular accounts, not in retirement
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.